About Acasti Pharma (CVE:ACST)
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolCVE:ACST
CUSIPN/A
Phone+1-450-6864555
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-162.34%
Return on Assets-103.36%
Miscellaneous
EmployeesN/A
Outstanding Shares25,605,000
Acasti Pharma (CVE:ACST) Frequently Asked Questions
What is Acasti Pharma's stock symbol?
Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST."
Who are some of Acasti Pharma's key competitors?
Some companies that are related to Acasti Pharma include Pan Orient Energy (POE), Africa Energy (AFE), Atacama Pacific Gold (ATM), Strategic Oil & Gas (SOG), C-COM Satellite Systems (CMI), Ikkuma Resources (IKM), CRH Medical (CRM), Avante Logixx (XX), Aveda Transportation (AVE), Energold Drilling (EGD), Abcourt Mines (ABI), Crown Point Energy (CWV), Alderon Iron Ore (ADV), Champion Bear Resources (CBA), Hyperion Exploration (HYX), Oceanic Iron (FEO), New Zealand Energy (NZ) and North American Tungsten (NTC).
Who are Acasti Pharma's key executives?
Acasti Pharma's management team includes the folowing people:
- Roderick Noel Carter, Executive Chairman of the Board
- Janelle D'Alvise, President, Chief Executive Officer, Director
- Linda Parinella O'Keefe, Chief Financial Officer
- Pierre Lemieux Ph.D., Chief Operating Officer
- Laurent Harvey, Vice President- Clinical and Non-Clinical Affairs
- Jean-Daniel Belanger, Secretary, Director- Corporate Affairs
- Jean-Marie Canan, Director (Age 61)
Has Acasti Pharma been receiving favorable news coverage?
Headlines about ACST stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acasti Pharma earned a news impact score of 0.23 on Accern's scale. They also assigned news headlines about the company an impact score of 45.88 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Acasti Pharma?
Shares of ACST and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Acasti Pharma's stock price today?
One share of ACST stock can currently be purchased for approximately C$1.31.
How big of a company is Acasti Pharma?
Acasti Pharma has a market capitalization of C$33.54 million.
How can I contact Acasti Pharma?
Acasti Pharma's mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The company can be reached via phone at +1-450-6864555.
MarketBeat Community Rating for Acasti Pharma (ACST)
MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe ACST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days.
Acasti Pharma (CVE:ACST) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 4/22/2016 forward)
Acasti Pharma (CVE:ACST) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Acasti Pharma (CVE ACST) Insider Trading and Institutional Ownership History
Acasti Pharma (CVE ACST) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/21/2017 | Jean-Daniel Bélanger | Director | Sell | 51,199 | C$2.41 | C$123,389.59 | | |
(Data available from 1/1/2013 forward)
Acasti Pharma (CVE ACST) News Headlines
| Source: |
|
Acasti Pharma (CVE:ACST) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Acasti Pharma (CVE ACST) Stock Chart for Sunday, April, 22, 2018
Loading chart…
